Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Apr 17:14:1149987.
doi: 10.3389/fimmu.2023.1149987. eCollection 2023.

FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review

Affiliations
Case Reports

FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review

Jia-Xin Yang et al. Front Immunol. .

Abstract

Background: FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) has been identified increasingly frequently in recent years. However, this rare MOG antibody disease may coexist with anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARe), in an overlap syndrome with unknown clinical features and prognosis.

Methods: We report a new case of this overlap syndrome and present a systematic review of similar cases in the literature to provide information on the clinical presentation, MRI features, EGG abnormalities, treatment, and prognosis of patients with this rare syndrome.

Results: A total of 12 patients were analyzed in the study. The most common clinical manifestations of FLAMES overlaid with anti-NMDARe were epilepsy (12/12), headache (11/12), and fever (10/12). Increases in intracranial pressure (median: 262.5 mmH2O, range: 150-380 mmH2O), cerebrospinal fluid (CSF) leukocyte count (median: 128×106/L, range: 1-610×106/L), and protein level (median: 0.48 g/L) were also observed. The median CSF anti-NMDAR antibody titer was 1:10 (1:1-1:32), while the median serum MOG antibody titer was 1:32 (1:10-1:1024). Seven cases exhibited unilateral cortical FLAIR hyperintensity, and five cases (42%) had bilateral cortical FLAIR hyperintensity, including four cases involving the bilateral medial frontal lobes. Of the 12 patients, five showed lesions at other sites (e.g., the brainstem, corpus callosum, or frontal orbital gyrus) before or after the development of cortical encephalitis. EEG showed slow waves in four cases, spike-slow waves in two cases, an epileptiform pattern in one case, and normal waves in two cases. The median number of relapses was two. Over a mean follow-up period of 18.5 months, only one patient experienced residual visual impairment, while the remaining 11 patients had good prognoses.

Conclusion: FLAMES alone is difficult to distinguish from overlap syndrome based on clinical features. However, FLAMES with bilateral medial frontal lobe involvement suggests the presence of the overlap syndrome.

Keywords: FLAIR; MOG ab-positive CCE; anti-N-methyl-D-aspartate receptor encephalitis; demyelinating disease; symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
(A) T-2 FLAIR hyperintensity in the right frontal cortex, swelling of brain tissue, and shallowing of the cerebral sulcus. (B) Abnormal enhancement of the pia mater in the right frontal lobe.
Figure 3
Figure 3
F7-AV, T3-AV, T5-AV: the left temporal region exhibits predominantly sharp-wave activity in the anterior and middle temporal regions, with some involvement of the posterior temporal region. F8-AV, T4-AV: The right anterior middle temporal region exhibits slow-wave activity.

Similar articles

Cited by

References

    1. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. Lancet Neurol (2023) 22(3):268–82. doi: 10.1016/S1474-4422(22)00431-8 - DOI - PubMed
    1. Budhram A, Mirian A, Sharma M. Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: Review of a novel clinico-radiographic spectrum. Front Neurol (2022) 13:1044642. doi: 10.3389/fneur.2022.1044642 - DOI - PMC - PubMed
    1. Reijerkerk A, Kooij G, van der Pol SM, Leyen T, Lakeman K, van Het Hof B, et al. . The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem (2010) 113(2):447–53. doi: 10.1111/j.1471-4159.2010.06598.x - DOI - PubMed
    1. Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. . Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol (2018) 75(1):65–71. doi: 10.1001/jamaneurol.2017.3196 - DOI - PMC - PubMed
    1. Martinez-Hernandez E, Guasp M, García-Serra A, Maudes E, Ariño H, Sepulveda M, et al. . Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology (2020) 94(22):e2302–10. doi: 10.1212/WNL.0000000000009239 - DOI - PubMed

MeSH terms